文献速递神经肿瘤

O-(2-18F-氟乙基)-L-酪氨酸正电子发射断层显像与灌注加权磁共振成像在进展性和复发性胶质瘤诊断中的比较:一项混合正电子发射断层/磁共振研究

Comparison of O-(2-18F-Fluoroethyl)-L-Tyrosine Positron Emission Tomography and Perfusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Patients with Progressive and Recurrent Glioma: A Hybrid Positron Emission Tomography/Magnetic Resonance Study.
PubMed 文献 · World Neurosurg · 2018-03-03

该研究纳入32例经治胶质瘤(25例进展或复发,7例治疗相关改变),用混合PET/MR扫描仪行18F-FET PET与PWI检查。18F-FET PET检出异常敏感性显著高于PWI(76% vs 52%,P=0.03),其最大肿瘤/脑比值可区分治疗相关改变与进展/复发胶质瘤(AUC 0.78,P=0.03,最佳截断值2.61,敏感性80%、特异性86%、准确性81%)。作者认为18F-FET PET诊断进展或复发胶质瘤优于PWI。

要点

  • 18F-FET PET检出经治胶质瘤异常的敏感性显著高于PWI(76% vs 52%,P=0.03)。
  • 18F-FET PET最大肿瘤/脑比值可区分治疗相关改变与进展/复发(AUC 0.78,P=0.03,截断值2.61)。
  • 两种模态均异常的患者中75%存在空间上不一致的局部热区。

核心结论

  • 这项先导研究提示,18F-FET PET诊断进展或复发胶质瘤优于PWI。

研究设计与样本

  • 研究纳入32例经治胶质瘤(25例进展或复发肿瘤,7例治疗相关改变),采用混合PET/MR扫描仪行18F-FET PET与PWI检查。

主要发现

  • 18F-FET PET检出经治胶质瘤异常的敏感性显著高于PWI(76% vs 52%,P=0.03)。
  • 18F-FET PET最大肿瘤/脑比值是唯一能区分治疗相关改变与进展或复发胶质瘤的参数(AUC 0.78,P=0.03,最佳截断值2.61,敏感性80%,特异性86%,准确性81%)。
  • 两种模态均显示信号异常的患者中,75%存在空间上不一致的局部热区。

局限性

  • 原文称本研究为先导研究(pilot study)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the diagnostic performance of O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) positron emission tomography (PET) and perfusion-weighted magnetic resonance imaging (PWI) for the diagnosis of progressive or recurrent glioma. METHODS: Thirty-two pretreated gliomas (25 progressive or recurrent tumors, 7 treatment-related changes) were investigated with 18F-FET PET and PWI via a hybrid PET/magnetic resonance scanner. Volumes of interest with a diameter of 16 mm were centered on the maximum of abnormality in the tumor area in PET and PWI maps (relative cerebral blood volume, relative cerebral blood flow, mean transit time) and the contralateral unaffected hemisphere. Mean and maximum tumor-to-brain ratios as well as dynamic data for 18F-FET uptake were calculated. Diagnostic accuracies were evaluated by receiver operating characteristic analyses, calculating the area under the curve. RESULTS: 18F-FET PET showed a significant greater sensitivity to detect abnormalities in pretreated gliomas than PWI (76% vs. 52%, P = 0.03). The maximum tumor-to-brain ratio of 18F-FET PET was the only parameter that discriminated treatment-related changes from progressive or recurrent gliomas (area under the curve, 0.78; P = 0.03, best cut-off 2.61; sensitivity 80%, specificity 86%, accuracy 81%). Among patients with signal abnormality in both modalities, 75% revealed spatially incongruent local hot spots. CONCLUSIONS: This pilot study suggests that 18F-FET PET is superior to PWI to diagnose progressive or recurrent glioma.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Verger A, Filss CP, Lohmann P, et al. Comparison of O-(2-18F-Fluoroethyl)-L-Tyrosine Positron Emission Tomography and Perfusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Patients with Progressive and Recurrent Glioma: A Hybrid Positron Emission Tomography/Magnetic Resonance Study. World Neurosurg. 2018. PMID: 29510293. doi:10.1016/j.wneu.2018.02.139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。